Results 161 to 170 of about 4,490 (182)

Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein

Neuro-Oncology, 2020
Holger Fischer, Mohammed Ullah, Axel Paehler   +2 more
exaly  

Entrectinib/temozolomide

Reactions Weekly, 2023
openaire   +1 more source

Carboplatin/entrectinib

Reactions Weekly, 2021
openaire   +1 more source

Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model

Cancer Letters, 2016
Suzanne P MacFarland, Venkatadri Kolla, Garrett M Brodeur   +2 more
exaly  

Entrectinib/sotorasib

Reactions Weekly, 2022
openaire   +1 more source

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Investigational New Drugs, 2019
Jong-Mu Sun, Jin Seok Ahn, Keunchil Park
exaly  

Alectinib/ceritinib/entrectinib

Reactions Weekly, 2022
openaire   +1 more source

LC–MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: and metabolic investigation

Journal of Pharmaceutical and Biomedical Analysis, 2018
Adnan Kadı, Mohamed W Attwa, Hany W Darwish   +2 more
exaly  

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Expert Opinion on Pharmacotherapy, 2020
Sehhoon Park, Jong-Mu Sun, Hyun Ae Jung
exaly  

Carboplatin/entrectinib/paclitaxel

Reactions Weekly, 2022
openaire   +1 more source